A survey of total adrenalectomy in cancer of the prostate

Macfarlane, David A.; Thomas, L.; Harrison, J. Hartwell

doi:10.1016/0002-9610(60)90151-3

Cited by 36 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We do indeed believe that the presence of significant levels of DHT in non-androgenic tissues, such as, for example, muscle (Geller et al 1978(Geller et al , 1984 (Morales et al 1955, MacFarlane et al 1960, Stoliar & Albert 1974, Ferguson 1975, Sogani etal. 1975, Sanford et al 1977, Markland et al 1978, Labrie et al 1983, 1984, 1985 Prior to our study published in 1982 , 'the effect of combination therapy had never been assessed as initial form of hormonal therapy' (Labrie et al 1983).…”

Section: S5s0^^ös0wmentioning

confidence: 90%

History of LHRH agonist and combination therapy in prostate cancer

Labrie¹,

Bélanger²,

Cusan³

et al. 1996

Endocrine Related Cancer

View full text Add to dashboard Cite

show abstract

Section: S5s0^^ös0wmentioning

confidence: 90%

History of LHRH agonist and combination therapy in prostate cancer

Labrie¹,

Bélanger²,

Cusan³

et al. 1996

Endocrine Related Cancer

View full text Add to dashboard Cite

show abstract

“…As mentioned earlier, the role of adrenal androgens has never been assessed early after diagnosis of prostate cancer. In fact, adrenalectomy or hypophysectorny [20,[42][43][44][45][46] has always been performed in patients showing relapse of their disease after previous castration or treatment with estrogens. The 20% to 40% positive responses observed by these authors is in agreement with the 20% to 55% rate of response observed in the present study and is a clear indication that the partial hormonal therapy administered to these patients left growing a proportion of tumor cells that are still sensitive to further androgen withdrawal.…”

mentioning

confidence: 99%

New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens

et al. 1983

View full text Add to dashboard Cite

To completely eliminate androgens of both testicular and adrenal origin, 37 previously untreated patients with advanced (stages C or D) prostatic cancer received the combination therapy using an LHRH agonist (HOE-766) and a pure antiandrogen (RU-23908). The response criteria developed by the National Prostatic Cancer Project were used. A positive response (assessed by bone scan and/or serum prostatic acid phosphatase measured by radioimmunoassay was observed in 29 of the 30 cases who could be evaluated by these objective criteria (97%). The objective response was parallel to a rapid and marked improvement of the clinical signs and symptoms related to prostate cancer (prostatism, bone pain, and general well being). In marked contrast, the same combination therapy applied to patients previously treated with high doses of diethylstilbestrol (13 patients) showed a positive objective response in only 55% of cases. In 23 previously castrated patients showing relapse, an objective response was seen in only 25% of cases after neutralization of adrenal androgens by the antiandrogen. Previous treatment with chlorotrianisene (TACE) had no detectable effect on prostatic cancer and patients having previously received such treatment had a rate of positive response similar to previously untreated patients (five of five). In the previously untreated patients receiving the combination therapy, a 60% fall in serum prostatic acid phosphatase was observed as early as five days after starting treatment, at a time when the serum androgen concentration was 100% to 200% above control. Combined treatment with the pure antiandrogen completely prevents flare-up of the disease, a complication previously found in a significant proportion of patients treated with an LHRH agonist alone. The present data show that complete withdrawal of androgens by combined hormonal therapy with the LHRH agonist (or castration) and a pure antiandrogen leads to a positive objective response in more than 95% of cases as opposed to 60%-70% as reported by many groups using the previous partial hormonal therapy (castration or high doses of estrogens). Adrenal androgens are most likely responsible for this difference. The present study also shows that the proportion of androgen-sensitive cells decreases from more than 95% in untreated patients to 25% to 55% after previous partial hormonal therapy. Such data clearly indicate that the previous partial hormonal therapy exclusively aimed at neutralizing testicular androgens left 25% to 55% of cancer cells having a relatively low sensitivity to androgens in a hormonal milieu compatible with their continuous growth. No clinical or biochemical side effect could be detected except those related to reduced serum androgen levels.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

“…Recently a new compound, estramustine phosphate (Estracyt)2 has been tested and may be efficacious in advanced disease [95][96][97][98]. Various surgical ablation proce dures to reduce androgen levels have been tested [99][100][101]. Analysis of DNA and RNA polymerase, as keys to rates of cell metabolism and protein synthesis, and degradation patterns of administered hormones have been done to elucidate the role of hormones in prostatic activity [102][103][104][105][106], An extensive review and discussion of new data indicating that cyproterone can block specific DNA synthesis during the Gi phase was presented [107].…”

Section: Hormonal Studiesmentioning

confidence: 99%

A Status Report – Human Prostatic Carcinoma, with Emphasis on Potential for Viral Etiology

Rf¹,

Sk²,

Js³

et al. 1977

Oncology

View full text Add to dashboard Cite

Several parameters of the biology of cancer of the prostate have been reviewed with a continuing assessment of the possible etiologic role of virus. These aspects include epidemiology, clinical studies, morphology, pathology, enzymology, immunology, endocrinology, model animal studies, in vitro systems, and viral investigations. From available literature it is concluded that, to date, the association with several urogenital tissues of herpes-type viruses has been best documented. It is suggested that a fundamental barrier to more sophisticated virologic and biologic studies is the lack of long term cell cultures of normal and pathologic prostate epithelium from males of all ages.

show abstract

A survey of total adrenalectomy in cancer of the prostate

Cited by 36 publications

References 15 publications

History of LHRH agonist and combination therapy in prostate cancer

History of LHRH agonist and combination therapy in prostate cancer

New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens

A Status Report – Human Prostatic Carcinoma, with Emphasis on Potential for Viral Etiology

Contact Info

Product

Resources

About